Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

While melanoma is much less common than other types of skin cancer, it is the most serious because it is more likely to ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

Several experiments were conducted to test whether the newly developed in vitro protocol enhanced the therapeutic efficacy of T cells for melanoma treatment in mouse models. Experimental findings ...

A transient increase in IOP led to temporary axial length elongation and subfoveal choroidal thinning in participants with and without myopia. The post-IOP changes were similar regardless of ...

Introduction: Ocular melanoma (OM) is a rare but lethal subtype of melanoma. This study develops a prognostic nomogram for OM using machine learning and internal validation techniques, aiming to ...

Ireland: A recent study conducted as part of the Myopia Outcome Study of Atropine in Children (MOSAIC) clinical trial explored the long-term effects of 0.01% atropine eye drops on macular choroidal ...

The treatment landscape for melanoma saw significant advancements in 2024, as highlighted by Elisa Funck-Brentano, MD, PhD, from Ambroise-Paré Hospital in Paris, France, during her presentation ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...